LRRK2-IN-1 (LRRK2-IN 1; LRRK2 IN-1) is a novel, highly potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2) with anti-PD (Parkinson’s disease) activity.

CZC-25146 is a potent, selective, and metabolically stable LRRK2 inhibitor (Leucine-rich repeat kinase-2) with IC50 of 4.76 nM and 6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.

GSK2578215A (GSK-2578215A; GSK 2578215A; GSK-2578215 A) is a novel, highly potent and selective LRRK2 kinase inhibitor with anti-PD (Parkinson’s disease) activity.

PF-06454589 is an analog of PF-06447475 which is a highly potent, brain penetrant and selective LRRK2 inhibitor which has been profiled in in vivo safety and pharmacodynamic studies.

GNE-9605 (GNE 9605; GNE9605) is a novel, brain-penetrant, highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor with anti-PD (Parkinson’s disease) activity.

GNE-7915 (GNE 7915; GNE7915) is a novel, highly potent, selective, and brain-penetrant leucine-rich repeat kinase 2 (LRRK2) inhibitor with anti-PD (Parkinson’s disease) activity.

GNE-0877 (GNE 0877; GNE0877) is a novel, highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor with important biological activity.

HG-10-102-01 (LRRK2 inhibitor 1) is a novel, potent and selective inhibitor of wild-type LRRK2 (leucine-rich repeat kinase 2) with an IC50 of 23.3 nM.

CZC-54252 HCl (CZC54252) is a novel and potent LRRK2 (leucine-rich repeat kinase 2) inhibitor with a potential for Parkinson’s disease (PD).

GNE-7915 tosylate is a novel, highly potent, selective, and brain-penetrant leucine-rich repeat kinase 2 (LRRK2) inhibitor, with IC50 and Ki of 9 nM and 1 nM, respectively.